Yves Cottin
Yves Cottin is an expert in Cardiology at Centre Hospitalier Universitaire Dijon Bourgogne (France). As of October 2026, ScienceLeadR ranks Yves Cottin in the top 1% of experts worldwide for Myocardial Ischemia, Coronary Disease and Arteriosclerosis. Yves Cottin has authored 837 publications, the most recent in 2026, and is an investigator in 55 clinical trials, 3 of them ongoing. SLR score: 2,726 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Pharmacy - Biostatistics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1993 - 2026
Number : 837
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Predictors of cardiac rehabilitation completion after acute myocardial infarction in young women: the French WAMIF Registry. PMID 42729979 — registries, absenteeism, myocardial infarction, cardiac rehabilitation, rehabilitation, st elevation myocardial infarction, risk factors | Eur Heart J Open | 2026 | 0 |
| Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial. PMID 42507445 — hemoglobins, myocardial infarction, anemia, heart failure, probability, heart, clinical medicine | JAMA Netw Open | 2026 | 0 |
| Leukocyte activation and inflammation in acute myocardial infarction: novel insights from cell population data. PMID 42490811 — cells, mortality, monocytes, myocardial infarction, neutrophils, biomarkers, immune system diseases, leukocytes, fatty acids | Front Immunol | 2026 | 0 |
| Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. PMID 41739450 — hemorrhage, myocardial infarction, incidence, rivaroxaban, cardiovascular diseases, st elevation myocardial infarction, thrombosis | JAMA Cardiol | 2026 | 0 |
| Association Between Recreational Drug Use and Cardiovascular Events Post-Hospitalization in France. PMID 41697269 — hospitalization, incidence, pharmaceutical preparations, recreational drug use, cardiovascular diseases, drug users, intensive care units, prognosis | Circ Popul Health Outcomes | 2026 | 0 |
Clinical Studies 55
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME CV) 2024-516652-18-00 — cardiovascular diseases, obesity, therapeutics, overweight | Phase 3 | Recruiting | 2025 |
| Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO FH Study) NCT06960902 — hyperlipoproteinemia type ii, research design, cardiovascular diseases, angiography, atherosclerosis, hypercholesterolemia, hyperlipoproteinemias | N/A | Recruiting | 2025 |
| Addiction in Intensive Cardiac Care Units NCT05063097 — dronabinol, antidepressive agents, research design, buprenorphine, heart diseases, n-methyl-3,4-methylenedioxyamphetamine, heroin, hospitalization, cocaine, methadone, pharmaceutical preparations, benzodiazepines, heart, substance-related disorders, psychotropic drugs, prevalence, tobacco use, intensive care units, barbiturates, amphetamines, smoking, cannabinoids, antidepressive agents, tricyclic, illicit drugs | N/A | Active not recruiting | 2021 |
LeadR Networks
Main global connection map